These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 34272069)

  • 1. [Eczematiform eruption after Pfizer-BioNTech COVID-19 vaccine].
    Bekkali N; Allard T; Lengellé C; Estève E
    Therapie; 2021; 76(4):364-365. PubMed ID: 34272069
    [No Abstract]   [Full Text] [Related]  

  • 2. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS).
    Welsh KJ; Baumblatt J; Chege W; Goud R; Nair N
    Vaccine; 2021 Jun; 39(25):3329-3332. PubMed ID: 34006408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020.
    Oliver SE; Gargano JW; Marin M; Wallace M; Curran KG; Chamberland M; McClung N; Campos-Outcalt D; Morgan RL; Mbaeyi S; Romero JR; Talbot HK; Lee GM; Bell BP; Dooling K
    MMWR Morb Mortal Wkly Rep; 2020 Dec; 69(50):1922-1924. PubMed ID: 33332292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-immunoglobulin E-mediated allergy associated with Pfizer-BioNTech coronavirus disease 2019 vaccine excipient polyethylene glycol.
    Jiang SY; Smith EM; Vo V; Akdis C; Nadeau KC
    Ann Allergy Asthma Immunol; 2021 Dec; 127(6):694-696. PubMed ID: 34547440
    [No Abstract]   [Full Text] [Related]  

  • 6. Generalized eczematous reactions to the Pfizer-BioNTech COVID-19 vaccine.
    Leasure AC; Cowper SE; McNiff J; Cohen JM
    J Eur Acad Dermatol Venereol; 2021 Nov; 35(11):e716-e717. PubMed ID: 34236729
    [No Abstract]   [Full Text] [Related]  

  • 7. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020.
    ;
    MMWR Morb Mortal Wkly Rep; 2021 Jan; 70(2):46-51. PubMed ID: 33444297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021.
    Wallace M; Woodworth KR; Gargano JW; Scobie HM; Blain AE; Moulia D; Chamberland M; Reisman N; Hadler SC; MacNeil JR; Campos-Outcalt D; Morgan RL; Daley MF; Romero JR; Talbot HK; Lee GM; Bell BP; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 May; 70(20):749-752. PubMed ID: 34014913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood pressure increase after Pfizer/BioNTech SARS-CoV-2 vaccine.
    Zappa M; Verdecchia P; Spanevello A; Visca D; Angeli F
    Eur J Intern Med; 2021 Aug; 90():111-113. PubMed ID: 34158234
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of BNT162b2 (Pfizer-BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients.
    Kaiser RA; Haller MC; Apfalter P; Kerschner H; Cejka D
    Kidney Int; 2021 Sep; 100(3):697-698. PubMed ID: 34270945
    [No Abstract]   [Full Text] [Related]  

  • 11. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.
    Chagla Z
    Ann Intern Med; 2021 Feb; 174(2):JC15. PubMed ID: 33524290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morbilliform rash after administration of Pfizer-BioNTech COVID-19 mRNA vaccine.
    Jedlowski PM; Jedlowski MF
    Dermatol Online J; 2021 Jan; 27(1):. PubMed ID: 33560802
    [No Abstract]   [Full Text] [Related]  

  • 13. Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses.
    Abu-Raddad LJ; Chemaitelly H; Yassine HM; Benslimane FM; Al Khatib HA; Tang P; Malek JA; Coyle P; Ayoub HH; Al Kanaani Z; Al Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul Rahim HF; Nasrallah GK; Al Kuwari MG; Al Romaihi HE; Al-Thani MH; Al Khal A; Butt AA; Bertollini R
    J Travel Med; 2021 Oct; 28(7):. PubMed ID: 34050372
    [No Abstract]   [Full Text] [Related]  

  • 14. COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society.
    Nojszewska M; Kalinowska A; Adamczyk-Sowa M; Kułakowska A; Bartosik-Psujek H
    Neurol Neurochir Pol; 2021; 55(1):8-11. PubMed ID: 33555604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent maculopapular rash after the first dose of Pfizer-BioNTech COVID-19 vaccine.
    Ackerman M; Henry D; Finon A; Binois R; Esteve E
    J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):e423-e425. PubMed ID: 33783017
    [No Abstract]   [Full Text] [Related]  

  • 16. In brief: Pfizer/BioNTech COVID-19 vaccine authorized for adolescents 12-15 years old.
    Med Lett Drugs Ther; 2021 May; 63(1625):81. PubMed ID: 34101717
    [No Abstract]   [Full Text] [Related]  

  • 17. Pfizer-BioNTech SARS-CoV-2 mRNA vaccine-associated erythema multiforme.
    Borg L; Mercieca L; Mintoff D; Micallef D; Pisani D; Betts A; Scerri L
    J Eur Acad Dermatol Venereol; 2022 Jan; 36(1):e22-e24. PubMed ID: 34547125
    [No Abstract]   [Full Text] [Related]  

  • 18. An Additional Case of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.
    Maas RJ; Gianotten S; van der Meijden WAG
    Am J Kidney Dis; 2021 Aug; 78(2):312. PubMed ID: 33992727
    [No Abstract]   [Full Text] [Related]  

  • 19. Relapse of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.
    Komaba H; Wada T; Fukagawa M
    Am J Kidney Dis; 2021 Sep; 78(3):469-470. PubMed ID: 34023417
    [No Abstract]   [Full Text] [Related]  

  • 20. Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 Vaccine: an Italian single-centre case series.
    Corbeddu M; Diociaiuti A; Vinci MR; Santoro A; Camisa V; Zaffina S; El Hachem M
    J Eur Acad Dermatol Venereol; 2021 Aug; 35(8):e483-e485. PubMed ID: 33834563
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.